Feeds

Final drug trial victim out of the woods

As placebo man balks at follow-ups

Securing Web Applications Made Simple and Scalable

All of the volunteers given an experimental immune drug in a London trial have now made it off the critical list at Northwick Park hospital.

The last of six men given biotech firm TeGenero's TGN1412 compound is now fully conscious and looks set to make a full recovery.

Intensive care clinical director Dr Ganesh Suntharalingam said: "We are delighted that the six patients have come through safely from the most critical stage of their condition."

He praised intensive care staff for how they dealt with the victims' very serious condition when they were transferred there from a private testing unit more than three weeks ago.

TeGenero said today its preliminary investigations showed it had followed all correct procedures in the animal testing phase of the drug. It also says the problem was unforseeable based on preclinical results (see here for why many think the problems might have been foreseeable though).

Watchdog the Medicines and Healthcare products Regulatory Agency (MHRA) agreed, saying it hasn't been able find a problem with how the trial was carried out.

It also couldn't find evidence of contamination of the drug. Some had speculated bacterial toxins might be responsible for the multiple organ failure.

MRHA added that its findings are not yet conclusive, but that the suspected flaws in the action of the drug itself were the most likely cause. The Secretary of State for Health is assembling a panel of experts to investigate why the animal trials didn't pick up the near-deadly complications.

Meanwhile, Raste Khan, 23, one of the men given a harmless placebo, appeared in The Sun today, saying he was still traumatised by what he saw during the trials. "I still feel haunted by it and I know my family have been extremely upset. I am too frightened even to get sleeping pills from the doctor."

He claims test contractor Parexel is demanding he honour the terms of his contract by attending follow-ups in order to pocket his £2,000 volunteer fee.

Testing contractor Parexel was unavailable for comment. ®

HP ProLiant Gen8: Integrated lifecycle automation

More from The Register

next story
Malaysian Airlines flight MH17 claimed lives of HIV/AIDS cure scientists
Researchers, advocates, health workers among those on shot-down plane
The Sun took a day off last week and made NO sunspots
Someone needs to get that lazy star cooking again before things get cold around here
Mwa-ha-ha-ha! Eccentric billionaire Musk gets his PRIVATE SPACEPORT
In the Lone Star State, perhaps appropriately enough
MARS NEEDS OCEANS to support life - and so do exoplanets
Just being in the Goldilocks zone doesn't mean there'll be anyone to eat the porridge
Diary note: Pluto's close-up is a year from … now!
New Horizons is less than a year from the dwarf planet
Forty-five years ago: FOOTPRINTS FOUND ON MOON
NASA won't be back any time soon, sadly
prev story

Whitepapers

Top three mobile application threats
Prevent sensitive data leakage over insecure channels or stolen mobile devices.
The Essential Guide to IT Transformation
ServiceNow discusses three IT transformations that can help CIO's automate IT services to transform IT and the enterprise.
Mobile application security vulnerability report
The alarming realities regarding the sheer number of applications vulnerable to attack, and the most common and easily addressable vulnerability errors.
How modern custom applications can spur business growth
Learn how to create, deploy and manage custom applications without consuming or expanding the need for scarce, expensive IT resources.
Consolidation: the foundation for IT and business transformation
In this whitepaper learn how effective consolidation of IT and business resources can enable multiple, meaningful business benefits.